Despite strong growth, Silence Therapeutics' high P/S ratio ...

Despite strong growth, Silence Therapeutics' high P/S ratio and weak revenue outlook suggest a risk of share price decline. Analysts lack confidence in a business turnaround, indicating potential risk for shareholders and potential investors.